Besides, a combination treatment by NEDD4-1 and WWP1 inducers for melanoma cancer, NEDD4-1 and ITCH inhibitors for prostate cancer, NEDD4-1 and SMURF1 for the HCC, as well as SMURF2 inducers and ITCH inhibitors for the breast cancer can be considered as the effective therapeutic approaches. This evidence concerns the gene SMURF2 and prostate carcinoma.